Search Results
Aug 03, 2026, 09:00 ET BOTOX® (toxina botulínica A) recebe aprovação da Anvisa para uso no músculo platisma
impacto positivo na qualidade de vida", afirma Fabio Crema, diretor médico da Allergan Aesthetics no Brasil.Nos estudos clínicos de Fase III2,4,5, o medicamento foi bem tolerado e demonstrou perfil consistente ao já estabelecido em outras indicações estéticas. A avaliação incluiu ensaios
More news about: Allergan
Aug 03, 2026, 08:54 ET Blue Chip Medical's Pro-Daptive™ SensorCell™ Ushers in a New Era of Advanced Pressure Injury Treatment
Incorporating patented SensorCell™ technology, this advanced system was developed for the prevention and treatment of complex pressure injuries, including Stage III, Stage IV, and unstageable wounds, as well as post-flap and post-graft care. Designed for hospitals, wound care clinics, long-term care facilities,
More news about: Blue Chip Medical Products, Inc.
Aug 03, 2026, 08:46 ET A Bitmine Immersion Technologies (BMNR) anuncia que suas reservas de ETH atingiram 5,8 milhões de tokens e que suas reservas totais em criptomoedas e caixa somam US$ 11,3 bilhões.
continua contando com o apoio de um grupo de investidores institucionais de destaque, incluindo Cathie Wood, da ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e o investidor individual Thomas 'Tom' Lee, para apoiar sua meta de adquirir 5% do ETH.NORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.8 Million Tokens, and Total Crypto and Total Cash Holdings of $11.3 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.8 Million Tokens, and Total Crypto and Total Cash Holdings of $11.3 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) gibt bekannt, dass der ETH-Bestand 5,8 Millionen Token erreicht hat und die gesamten Krypto- und Bargeldbestände 11,3 Milliarden US-Dollar betragen
wird weiterhin von einer Gruppe führender institutioneller Investoren unterstützt, darunter Cathie Wood von ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital und der Privatinvestor Thomas „Tom" Lee, um das Ziel von Bitmine zu unterstützen, 5 % der ETH zu erwerben
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) anuncia que sus tenencias de ETH alcanzan los 5,8 millones de tokens
con el respaldo de un selecto grupo de inversores institucionales, entre los que se incluyen Cathie Wood de ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital y el inversor particular Thomas "Tom" Lee, para apoyar el objetivo de Bitmine de adquirir el 5% de ETH.
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Công Bố Lượng ETH Nắm Giữ Đạt 5,8 Triệu Token, Đưa Tổng Tài Sản Tiền Mã Hóa và Tiền Mặt Lên Mức 11,3 Tỷ USD
Bitmine hiện vẫn được hỗ trợ bởi một nhóm các nhà đầu tư tổ chức hàng đầu như Cathie Wood của ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital và nhà đầu tư cá nhân Thomas "Tom" Lee nhằm giúp Bitmine đạt mục tiêu sở hữu 5% ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Aug 03, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete B1 Activation System with 600mg Research-Matched Dose and Full Cofactor Support
levels 196% higher at equivalent doses (Xie et al., 2014). The BENDIP Phase III trial—the largest, highest-quality benfotiamine study conducted—used 600mg benfotiamine daily and demonstrated an 82.5% response rate in BENDIP Phase III trial participants for nerve-related outcomes, with 600mg producing statistically
More news about: Triquetra Health LLC
Aug 03, 2026, 08:00 ET Carver Bancorp, Inc. Announces Agreement with EJF Capital to Cancel Interest in Exchange for Shares of Common Stock
Exchange Agreement follows the previously announced cancellation of more than $1 million in interest obligations by TruPS holder EJF.Lewis P. Jones III, Chairman of the Board of Directors of Carver, said, "We welcome EJF's continued support and are gratified by the confidence demonstrated by EJF in our
More news about: Carver Bancorp, Inc.
Aug 03, 2026, 07:30 ET Lindblad Expeditions Holdings, Inc. Reports 2026 Second Quarter Financial Results
general economic and/or geopolitical factors that negatively impact the ability or desire of people to travel; (ii) loss of business due to competition; (iii) unscheduled disruptions in our business due to travel restrictions, weather events, mechanical failures, crew or guest illness such as a gastrointestinal
More news about: Lindblad Expeditions Holdings, Inc.
Aug 03, 2026, 07:17 ET Natural Grocers® Celebrates 71 Years With Beach-Worthy Savings, Freebies and a Chance to Win a Toyota® RAV4 Hybrid, Aug. 13-15, 2026
supplies last. No rain checks. Limit one per customer. Natural Grocers reserves the right to correct errors. Void where prohibited by law.[iii] Offer valid 8/14/2026 only from 3-5 p.m. at participating stores, while supplies last. No rain checks. Limit one per customer. Natural Grocers reserves
More news about: Natural Grocers by Vitamin Cottage, Inc.
Aug 03, 2026, 07:00 ET Marriott International Reports Second Quarter 2026 Results
1 "International" refers to: (i) Europe, Middle East & Africa, (ii) Greater China, (iii) Asia Pacific excluding China, and (iv) Caribbean & Latin America.
More news about: Marriott International, Inc.
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
received Phase III clearance from the U.S. Food and Drug Administration (FDA). ASC30 is the primary pillar of Ascletis' oral small molecule obesity portfolio. The Company has initiated a global Phase III program
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 05:45 ET Hyperscale Data Establishes Bitcoin-Backed DeFi Financing Program Through Morpho Protocol; Current Borrowings Approximately $30 Million at 4.9% to Support Michigan AI Data Center Expansion
long-term strategic initiatives."This is a significant milestone in the evolution of Hyperscale Data's capital strategy," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We believe Bitcoin is no longer simply a treasury asset—it is a strategic financial asset capable
More news about: Hyperscale Data Inc.
Aug 03, 2026, 05:00 ET HIZENERGY dołącza do światowej czołówki, trafiając na listę BloombergNEF Tier 1
specjalizujący się w sektorze energetycznym, opublikował listę producentów magazynów energii o wysokich parametrach technicznych (Tier 1) na III kwartał 2026 r. Założona zaledwie cztery lata temu w Chinach firma HIZENERGY znalazła się w tym prestiżowym zestawieniu, dołączając do światowej
More news about: HIZENERGY
Aug 03, 2026, 04:47 ET REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
member.According to the Complaint, the Company made false and misleading statements to the market. Regeneron led investors to believe that its Phase III Fianlimab-Libtayo Study was likely to succeed by achieving its primary endpoint. The Company utilized flawed statistical assumptions. In fact, the Company
More news about: Schall, Brown & Schwartz LLP
Aug 03, 2026, 04:43 ET Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN
According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company's study ultimately failed to achieve its primary
More news about: DJS Law Group LLP
Aug 03, 2026, 02:56 ET GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
the Company made false and misleading statements to the market. Grail misled investors about the prospects of its NHS-Galleri trial in reducing Stage III-IV cancers, concealing adverse facts from the trial while describing it positively. The Company's optimism related to the NHS-Galleri study was overstated,
More news about: Schall, Brown & Schwartz LLP
Aug 02, 2026, 08:43 ET GRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint
More news about: THE ROSEN LAW FIRM, P. A.
Jul 31, 2026, 22:00 ET Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and approximately 29% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
delivery even if timely provision was possible; (iii) as a result of (i)-(ii) above, the Company had materially misrepresented demand for its optical wavelength services and the nature of its "backlog" of wavelength orders; (iv) as a result of (i)-(iii) above, the Company was not on track to achieve its
More news about: Kahn Swick & Foti, LLC
Jul 31, 2026, 22:00 ET Wix.com Ltd. Notice of September 22, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
to those offered by other companies; (ii) the Company had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements
More news about: Kahn Swick & Foti, LLC
Jul 31, 2026, 22:00 ET ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; (iv) as a result, Defendants' statements about the Company's business, operations, and prospects were
More news about: Kahn Swick & Foti, LLC
Jul 31, 2026, 22:00 ET Zillow Group Securities Fraud Class Action Arising from Alleged Anticompetitive Agreement and Related Regulatory Risks - Investors May Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
(ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's
More news about: Kahn Swick & Foti, LLC
Jul 31, 2026, 22:00 ET EquipmentShare.com Inc. Notice of September 21, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
transactions; (ii) the Company had not terminated or substantially reduce a number of the transactions with entities owned or controlled by the co-founders; (iii) as a result, the Company's financial statements were materially misleading; and (iv) that, as a result of the foregoing, Defendants' positive statements
More news about: Kahn Swick & Foti, LLC